Related Experiment Video

Updated: Dec 9, 2025

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

8.1K

Neuropsychiatric profiles in mild cognitive impairment with Lewy bodies

Chunyan Liu1,2, Shuai Liu3,4, Xiaodan Wang3

  • 1Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Beijing, China.

Aging & Mental Health
|September 8, 2020
PubMed
Abstract

Insights

Patients with mild cognitive impairment with Lewy bodies (MCI-LB) exhibit more neuropsychiatric symptoms, including visual hallucinations and rapid eye movement sleep behavior disorder (RBD), than those with mild cognitive impairment due to Alzheimer's disease (MCI-AD). These symptoms aid in differentiating MCI-LB from MCI-AD.

Area of Science:

  • Neurology
  • Neuroscience
  • Psychiatry

Background:

  • Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
  • Distinguishing between subtypes of MCI, such as MCI with Lewy bodies (MCI-LB) and MCI due to Alzheimer's disease (MCI-AD), is crucial for prognosis and management.
  • Neuropsychiatric symptoms (NPS) are common in cognitive impairment but their patterns may differ across etiologies.

Purpose of the Study:

  • To compare the spectrum and severity of neuropsychiatric symptoms (NPS) in patients diagnosed with mild cognitive impairment with Lewy bodies (MCI-LB) versus those with mild cognitive impairment due to Alzheimer's disease (MCI-AD).
  • To identify specific NPS that can help differentiate between MCI-LB and MCI-AD.

Main Methods:

  • A cross-sectional study involving patients with probable MCI-LB (n=53), MCI-AD (n=60), dementia with Lewy bodies (DLB, n=97), and Alzheimer's disease (AD, n=202), all over 60 years old.
  • Neuropsychiatric profiles were assessed using the Neuropsychiatric Inventory (NPI).
  • The Lewy Body Neuropsychiatric Supportive Symptom Count (LBNSSC) was employed to quantify key supportive features of DLB, including systematized delusions, non-visual hallucinations, apathy, anxiety, and depression.

Main Results:

  • Patients with MCI-LB demonstrated significantly higher total NPI scores for both prevalence and severity compared to MCI-AD patients.
  • The MCI-LB group exhibited a greater prevalence and severity of visual hallucinations and rapid eye movement sleep behavior disorder (RBD) than the MCI-AD group.
  • A higher proportion of MCI-LB patients (41.5%) presented with two or more supportive NPS compared to MCI-AD patients (20%), with a significant likelihood ratio (2.08, p=0.013). Apathy, depression, and appetite/eating disorders were prevalent in MCI-LB.

Conclusions:

  • The Neuropsychiatric Inventory (NPI) is an effective tool for detecting NPS in individuals with MCI-LB.
  • MCI-LB is characterized by a higher prevalence of core Lewy body features, such as visual hallucinations and RBD, and a higher LBNSSC compared to MCI-AD.
  • The identified NPS patterns, particularly visual hallucinations, RBD, and supportive symptoms, can aid in the clinical differentiation between MCI-LB and MCI-AD.
Keywords:
Mild cognitive impairment with Lewy bodiesNeuropsychiatric Inventoryneuropsychiatric symptoms

More Related Videos

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

8.1K
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
412
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
811
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
635